Iclusig® (ponatinib) – Expanded indication
December 18, 2020 - Takeda announced the FDA approval of Icusig (ponatinib), for the treatment of adult patients with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
Download PDF
